◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GHRS

GH Research PLC (GHRS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-13

GH Research PLC (GHRS) operates in the BIOTECHNOLOGY industry and is headquartered in Dublin, Ireland with about 73 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, GHRS reported $0M in revenue and ($48M) in net income.

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.

Interactive charts & full statements →

GHRS Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Total Revenue$0M$0M$0M$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M
Gross Margin %
Operating Income (EBIT)($71M)($61M)($50M)($41M)($31M)($15M)$0M$0M
Operating Margin %
Net Income($62M)($48M)($39M)($36M)($22M)($9M)$0M$0M
Net Margin %
EBITDA($64M)($47M)($39M)($35M)($22M)($9M)$0M$0M
Earnings Per Share (EPS)$-0.99$-0.79$-0.75$-0.68$-0.43$-0.18$-0.01$-0.01
Shares Outstanding (M)67M61M52M52M52M52M30M28M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GHRS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$0M$0M$0M$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M$0M$0M
Gross Margin %
Operating Income (EBIT)($19M)($19M)($17M)($17M)($15M)($13M)($13M)($13M)
Operating Margin %
Net Income($15M)($19M)($14M)($14M)($9M)($11M)($9M)($12M)
Net Margin %
EBITDA($15M)($19M)($17M)($14M)($9M)($11M)($9M)($12M)
Earnings Per Share (EPS)$-0.23$-0.31$-0.23$-0.23$-0.15$-0.19$-0.17$-0.23
Shares Outstanding (M)67M62M62M62M62M58M52M52M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GHRS Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash from Operations (CFO)($52M)($44M)($42M)($33M)($26M)($15M)$0M$0M
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($53M)($44M)($42M)($33M)($26M)($15M)$0M$0M
FCF Margin %

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GHRS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($15M)($11M)($12M)($14M)($9M)($9M)($10M)($12M)
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($15M)($11M)($12M)($14M)($9M)($9M)($10M)($12M)
FCF Margin %

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GHRS Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Total Assets$372M$288M$188M$226M$254M$280M$6M$1M
Cash & Cash Equivalents$345M$246M$101M$78M$166M$277M$6M$0M
Total Liabilities$13M$9M$9M$7M$5M$3M$0M$0M
Total Debt (Short + Long-Term)$0M$0M$0M$0M$0M$0M$0M$0M
Total Shareholders' Equity$359M$280M$179M$219M$250M$277M$6M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GHRS viewer.

Other Companies in BIOTECHNOLOGY

← GHMAll “G” companiesGHTA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.